Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Bladder cancer
Stage/Subtype:  stage II bladder cancer
Trial Type:  Treatment
Results 1-21 of 21 for your search:
Start Over
Transurethral Resection of Bladder Tumors Using PK Button Vaporization Electrode or Monopolar Loop Electrocautery in Treating Patients with Bladder Cancer
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 to 89
Trial IDs: WCI2119-11, NCI-2013-00065, IRB00053735, NCT01567462
Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1011, NCI-2011-02604, CDR0000686574, SWOG-S1011, NCT01224665
A Phase III Study of Atezolizumab Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy [IMvigor010]
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WO29636, NCI-2015-01334, 2014-005603-25, NCT02450331
A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: rAd-IFN-CS-003, NCI-2016-01157, NCT02773849
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients with Bladder Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8027, NCI-2013-01614, NCT01938573
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: HCRN GU14-188, NCI-2015-01257, NCT02365766
Gemcitabine Hydrochloride and Cisplatin in Treating Patients with High-Grade Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-208, NCI-2010-02376, NCT01261728
Gene Expression Profiling in Predicting Chemotherapy Response in Patients with Localized, Muscle-Invasive Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1314, NCI-2014-00850, NCT02177695
Robotic or Open Radical Cystectomy in Treating Patients with Bladder Cancer
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 4B-15-4, NCI-2016-00080, HS-15-00731, NCT02699853
Pembrolizumab, Gemcitabine Hydrochloride and Radiation Therapy in Treating Patients with Bladder Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S15-00220, NCI-2016-00717, NCT02621151
Gemcitabine Hydrochloride, Cisplatin, and Pembrolizumab before Surgery in Treating Patients with Muscle-Invasive Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC1520, NCI-2016-00790, NCT02690558
Image-Guided Radiation Therapy and Gemcitabine Hydrochloride in Treating Patients with Stage II-III Bladder Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 10-031, NCI-2010-01234, NCT01104350
Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TAR-200-101, NCI-2016-00507, NCT02722538
MRI Before and During Surgery in Diagnosing Patients With Bladder Cancer
Status: Active
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: OSU-08063, NCI-2012-00937, 2009C0001, NCT00938145
Intracorporeal or Extracorporeal Urinary Diversion during Robotic Assisted Radical Cystectomy in Reducing Complications in Patients with Bladder Cancer
Status: Not yet active
Phase: No phase specified
Type: Supportive care, Treatment
Age: Not specified
Trial IDs: CASE 7814, NCI-2014-01530, NCT02252393
BCG Solution in Treating Patients with Invasive Bladder Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HSC2014-0002H, NCI-2013-02367, CTRC 13-0051, NCT02365207
Radical Cystectomy or Chemotherapy and Radiation Therapy in Treating Patients with Muscle Invasive Bladder Cancer
Status: Enrolling by invitation
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CTMS# 15-2105, NCI-2016-00624, HSC2015-620H, NCT02716896
Observation or Immediate Surgery in Reducing Complications in Patients with Low Risk Bladder Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 50 and over
Trial IDs: VICC URO 15139, NCI-2016-00677, NCT02700724
sEphB4-HSA before Surgery in Treating Patients with Bladder Cancer, Prostate Cancer, or Kidney Cancer
Status: Not yet active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0S-15-6, NCI-2015-02236, NCT02767921
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Not yet active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
Durvalumab and Tremelimumab in Treating Patients with Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated with Cisplatin-Based Therapy before Surgery
Status: Not yet active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 2016-0033, NCI-2016-01147, NCT02812420
Start Over